Early-stage immunotherapy Mnemo is a Paris-based biotech focused on developing immunotherapies targeting tumour-specific E-antigens using in-silico and wet-lab pipelines, indicating a need for collaboration on target discovery platforms, preclinical services, or partnership in translational research.

EnfiniT platform focus With the EnfiniT platform as their core discovery engine and a recent preclinical CAR-T memory differentiation study, opportunities exist for提供 of gene editing tools, epigenetic modulation services, GMP-ready vector production, and contract research support to advance their CAR-T therapies.

Strategic hires & leadership Past leadership and business development hires (CEO, CBO, Scientific Co-Founder) suggest a growing emphasis on partnerships and fundraising; this presents openings for BD outreach, licensing discussions, and co-development or co-funding arrangements.

Funding and growth signals Initial Series A funding of $90M and RHU program participation signal readiness for collaborations that accelerate development timelines, including CRO/CMO partnerships, collaboration agreements, and co-investment opportunities to scale preclinical programs.

Small team, high potential With a lean 2-10 employee profile and a broad pipeline across cell therapy, TCE, ADC, and vaccines, Mnemo may seek strategic outsourcing, specialized vendors, and scalable service partners to support discovery campaigns, lead optimization, and translational research while maintaining agility.